VICTORIA, Dec. 26, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce Jason Orloske has accepted the position of Vice President of Operations for ImmunoPrecise Antibodies Global Division reporting directly to Dr. Jennifer Bath, CEO and President.
As Vice President of Operations, Jason Orloske, PMP, CSP, is responsible for operationalizing strategic initiatives and continuing to drive growth. Jason is a transformational business leader with almost 20 years' experience in project portfolio management and strategic delivery. He partners with executives and senior management teams to uncover challenges and opportunities that arise, and develops a right-sized strategy that aligns with organizational vision. "I'm excited to be a part of the ImmunoPrecise team and have the opportunity to serve our employees and shareholders around the globe. The first six months will focus on growth initiatives by expanding IPA's production capabilities as well as growing the sales and marketing staff in key regions," explains Jason Orloske. "Concurrent to these initiatives, we will implement global systems that drive efficiencies and provide real-time data, so we can monitor trends and make decisions faster."
Jason brings a diverse background to IPA. Much of his career has been spent in the consulting space focused on creating operational efficiencies and mergers and acquisitions. Most recently, Jason lead implementation management at WEX Health (health benefits SaaS platform), and Aldevron, where he managed the project management office (PMO). Jason holds a master's degree in project management from the University of Mary in Bismarck, ND, where he also taught as an adjunct professor.
"We are excited to welcome Jason to our senior leadership team," shares Dr. Jennifer Bath, IPA CEO and President. "Jason brings a unique vision for strategic development and managing companies experiencing exponential growth as well as a talent for building a strong company culture."
In efforts to align the new operational leadership with client and investor relations, IPA has entered into a master services agreement (the "Services Agreement") with Native Ads Inc. ("Native Ads") whereby Native Ads will provide digital media marketing services including content development, web development, media buying and distribution, and campaign reporting and optimization. In consideration of the services, ImmunoPrecise will pay Native Ads USD $150,000 during the term of the Services Agreement. Neither Native Ads nor any of its directors and officers own any securities of ImmunoPrecise. The Services Agreement is subject to the approval of the TSX Venture Exchange.
About Native Ads Inc.
Native Ads owns and operates a proprietary ad exchange with over 80 integrated SSPs (supply side platforms) resulting in access to 3-7 billion daily North American ad impressions.
The full-service ad agency arm leverages its proprietary platform and traffic buying methodologies to assist issuer clients with high volume content dissemination to appropriate audiences at the appropriate times.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.
The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hybridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.
For further information: For investor relations please contact: Frederick Chabot, Phone: 1-438-863-7071, Email: [email protected], Contact Financial Corp., 1450 - 701 West Georgia St., Vancouver, BC V7Y 1G5